Best GLP-1 Provider for Bariatric Revision: What to Do When the Weight Came Back

Bottom line: GLP-1 After Gastric Sleeve is an anatomy-first decision. If a surgeon finds a mechanical problem, severe reflux, an ulcer, an obstruction, or another complication, the bariatric program may be the better first call—even though this page earns nothing from that choice. If anatomy is stable and the problem is weight regain or an inadequate weight response, an FDA-approved GLP-1 is usually the lower-friction first step because it does not permanently change the anatomy and can be stopped or changed with a prescriber. Medication cannot repair a mechanical problem, and current evidence does not prove that it produces the same result as every revision operation.

URL: /best-glp-1-provider-for-bariatric-revision/

Title tag (63 characters): Best GLP-1 Provider for Bariatric Revision (2026 Data)

Meta description (151 characters): Regained weight after surgery? One study ran a GLP-1 against revision surgery. Same weight loss. 37% complications vs zero. Plus what insurers cover.

Eyebrow: Post-surgery weight recurrence · Verified against two insurer policies and three trials

How this page makes money: We may earn a commission if you use an eligible provider link. That does not change your price or this verdict. A bariatric surgeon or your existing care team may be the better next step, and this page earns nothing when you choose that path.

This online path fits only after a clinician has ruled out a problem that needs surgical or urgent evaluation. It is for a reader pursuing medical weight management with an FDA-approved drug—not for someone trying to treat vomiting, obstruction, bleeding, severe reflux, or another mechanical complication online.

By the Weight Loss Provider Guide Research Team Last verified: August 17, 2026 · What we actually checked ↓ · How we make money

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

The best GLP-1 provider for bariatric revision is Ro for most people who regained weight after a sleeve or bypass. It carries Zepbound® (tirzepatide) and the Wegovy® pen, it does your insurance paperwork for you, and it gives back the $39 start fee if you turn out not to qualify.

But here's the part nobody told you. You may not need the second surgery at all.

In 2026, researchers published the first randomized trial of semaglutide in people who had already had bariatric surgery and didn't get the result they hoped for. Over 68 weeks, the medication group lost 18% of their body weight. The placebo group gained 0.4%.

And in the one study that ever put a GLP-1 head to head against actual revision surgery, they came out nearly even on weight — 13 kg versus 17 kg over two years. The difference wasn't the scale. It was that 37% of the surgery patients had serious complications. Nobody in the medication group did.

Three things change that answer. If food gets stuck, you're throwing up a lot, you can't keep fluids down, or something hurts — call your surgeon, not a website. If your pouch or stoma has actually stretched, surgery is the right fix and your insurance probably covers it. And whichever route you pick, take the injection, not the pill. Your surgery changed the exact part of your stomach the pill needs to work.

One more thing worth knowing before you spend six months fighting for a revision: UnitedHealthcare's own written policy says revision surgery for anything other than a mechanical failure is "unproven and not medically necessary." Gaining weight back, by itself, may not open a door at all.

We'll show you the actual documents below.

Do not use a weight-loss comparison page to explain urgent symptoms. Severe or worsening abdominal or chest pain, repeated vomiting, inability to keep fluids down, black or bloody stool, fainting, trouble breathing, or signs of obstruction need prompt medical evaluation. This page cannot tell whether your post-surgery anatomy is stable.

Start here: which situation are you in?

GLP-1 After Gastric Sleeve: What Decides the Better First Move

The deciding fact is not how badly you want the weight off. It is whether the anatomy needs repair. Use the surgeon's workup to answer that first; then compare expected benefit, risk, cost, and reversibility.

You didn't fail. Here's what actually happened.

Answer capsule: Weight returning after bariatric surgery is a known physical event, not a personal failure. Roughly one in five people who have bariatric surgery either don't lose enough weight or regain it afterward. Surgeons have a formal name for it — weight recurrence — and the professional societies deliberately stopped calling it "failure" because obesity behaves like a chronic disease, not a choice.

Let's get this out of the way, because you can't make a good decision while you're ashamed.

You had your stomach cut. That is not a small thing. You did the hardest version of the hard thing. And then your body did what bodies with a chronic disease do — it pushed back.

Here is how the people who study this describe it. Around one in five people who have bariatric surgery either don't lose enough weight or regain it afterward. In one long-term study of gastric bypass patients, the average person had regained 27% of their maximum weight loss by the five-year mark. In a separate group of 300 bypass patients, 37% regained a quarter or more of everything they'd lost.

That's not a small unlucky subgroup. That's a normal outcome that happens to a lot of people.

The doctors even have precise words for it, and it helps to know them so you can use them back:

• Suboptimal clinical response means you lost less than 20% of your weight after surgery.
• Late postoperative clinical deterioration means you regained more than 30% of what you'd lost.

Those are the official definitions from IFSO, the international body of bariatric surgeons. Notice that neither one contains the word "failure." That was on purpose. The American Society for Metabolic and Bariatric Surgery — ASMBS, the main US surgical group — now prefers "weight recurrence" over "weight regain," because regain sounds like something you did and recurrence sounds like something that happened.

Why your appetite came back

Here's the mechanical version, in plain words.

Part of why your surgery worked was hormonal, not just mechanical. After a sleeve or a bypass, your gut starts releasing more GLP-1 — a hormone that tells your brain you're full. That's a real, measured effect. It's one of the reasons you weren't hungry in year one.

Over the years, that signal can fade. And when it fades, hunger comes back — not because you got weak, but because the hormone stopped shouting.

A GLP-1 medication puts that signal back. Same mechanism your surgery used. Delivered from the outside.

That's the whole idea. You're not replacing your surgery with a drug. You're restoring the part of your surgery that quieted down.

Real people say it like this, from public bariatric forums:

"I regained basically all of it."

"I feel like a utter failure."

If either of those is running in your head right now — that's the most common thought in this entire subject. It's also the least useful one. Shame is not a treatment plan.

Do you need a surgeon first, or a GLP-1 provider?

What the provider says vs what this page verified

Answer capsule: Contact your bariatric or surgical team first if you have repeat vomiting, trouble swallowing, food that gets stuck, ongoing pain, or a sudden change in how much you can eat. An online GLP-1 provider cannot look inside the anatomy your surgery created. If your symptoms are stable and the main change is returning hunger and slow weight gain, an obesity-medicine or telehealth evaluation is a reasonable next step.

This is the one section where we'd rather lose you than get this wrong.

An online provider can read your history. They can prescribe. They cannot run a scope down your throat or take an X-ray of your pouch. So there's one question that has to get answered before anything else:

Is this a plumbing problem, or a hunger problem?

Call your surgical team first if any of these are true

• Food feels like it gets stuck
• You're throwing up more than occasionally
• You can't keep enough fluids down
• Swallowing has gotten harder
• You have real or ongoing belly pain
• The amount you can eat changed suddenly, not slowly
• You're less than a year out from surgery
• A doctor already suspected something structural

Severe symptoms can need urgent care. Don't wait on a chat window for those.

A GLP-1 evaluation makes sense when

• Your surgical team already looked and things are fine
• No new stomach symptoms
• Hunger and cravings came back
• The weight came back slowly, over months or years
• You never got to the weight you were hoping for
• You want long-term medical support, not a one-time fix

If your original surgeon is gone

This happens a lot. Practices close, surgeons move, insurance changes.

Use the MBSAQIP accredited center finder — that's the joint accreditation program run by the American College of Surgeons and ASMBS, with close to 1,000 participating sites across the US and Canada. Those centers are set up to review someone else's surgery. You don't need to go back to the exact person who operated on you.

And here's the honest middle path

Most people reading this don't have to pick one. The real sequence usually looks like this:

1. Get your anatomy looked at
2. Pull your records and labs
3. Get a GLP-1 evaluation
4. Let both teams see the same numbers
5. Revisit a procedure only if it's still needed

ASMBS's own 2026 statement on weight recurrence says the same thing in more formal language — that non-response and weight recurrence after surgery should be handled case by case using medical, endoscopic, surgical, or combined treatment. Not one lane, forced on everyone.

Not sure which lane you're in? Take our free 60-second matching quiz → Four questions. No account. You get a plain-English answer about who to contact first and what to bring.

Does a GLP-1 actually work after bariatric surgery?

Answer capsule: Yes, and there is now randomized evidence for it. The BARI-STEP trial, published in Nature Medicine in 2026, gave weekly semaglutide 2.4 mg to adults at least one year past a sleeve or gastric bypass who had lost less than 20% of their weight from surgery. After 68 weeks, the semaglutide group lost 18.0% of their body weight. The placebo group gained 0.4%.

This is the study that changes the conversation, and almost nobody has written about it for patients yet.

What BARI-STEP did

Read that result line again. Not "some benefit." Not "may help." An 18% average loss against a placebo group that slightly gained — in people who had already had the surgery and already been told it hadn't worked well enough.

How many people actually responded

The headline number is an average, and averages hide people. So here's the breakdown from the semaglutide group:

A note on our own math, so you can check us. The semaglutide arm had 34 people in the final analysis. Run those percentages against 34 and you get exactly 29 people, exactly 21 people, and exactly 16 people. Whole humans, no rounding fudge. That's the arithmetic check we ran before we published these figures, and it's the kind of thing you should demand from any page quoting a trial at you.

So roughly six in seven lost at least a tenth of their body weight. Nearly half lost a fifth.

What BARI-STEP does not prove

We're going to be strict here, because this is exactly where health pages get sloppy and lose people's trust.

It did not compare medication to revision surgery. Nobody in this trial got a revision. So no one can honestly say "the trial proved the drug beats surgery." It didn't test that.

It did not test tirzepatide. It tested semaglutide 2.4 mg — the dose sold as Wegovy for weight management.

It did not test any pill or any compounded product. It was a weekly injection of an FDA-approved brand-name medication. Results from this trial cannot be transferred to a compounded product just because both are described with the word "semaglutide." Those are different products with different regulatory status, and we'll come back to that.

It did not test any telehealth company. No provider on this page — including the ones we recommend — can claim these results as theirs.

It was small. 70 people randomized, 63 in the final analysis. That's real randomized evidence, which is a big step up from what existed before. It's not a 2,000-person trial.

And there's a real catch in the body composition data. Lean soft tissue — muscle — went down during treatment. That's part of why the trial built resistance training and a structured diet into both arms. We're going to come back to this in the safety section, because for someone who has already had bariatric surgery and may already be behind on protein, this matters more than it does for the average person. It's also the single best reason to pick a provider that gives you real follow-up instead of a prescription and a shipping label.

The number nobody found, and it's the reassuring one

Before BARI-STEP, the best evidence in this group came from a 2021 study of 95 gastric bypass patients. We're about to spend a lot of time on that study. But one finding in it deserves its own moment.

In that study, only about 11% of the post-surgery patients failed to lose 5% of their body weight on the medication.

In the comparable trial of the same drug in people who had never had surgery, more than 35% failed to hit 5%.

Sit with that. Your biggest fear — the one you probably haven't said out loud — is that having surgery already used up your one shot, and now nothing will work. The evidence suggests the opposite. People who've had bariatric surgery appear to respond to these medications better than people who haven't.

Your surgery didn't ruin your chances. On this evidence, it may have improved them.

GLP-1 or revision surgery: which one actually wins?

Answer capsule: In the only study that put them side by side in the same patients, a GLP-1 injection and surgical revision produced nearly the same weight loss over two years — 13 kg versus 17 kg. The difference was risk: 37% of the surgery group had serious complications and none of the medication group did. The endoscopic option performed worst, reversing only 20% of regained weight, and every patient in that group asked for medication instead within 12 months.

This is the study we couldn't find on a single page currently ranking for this question. It's free to read. It's cited exactly once, buried in a reference list.

The setup

95 patients. All of them at least six years past a Roux-en-Y gastric bypass — nine years, on average. All of them had regained weight. Everyone who'd regained more than 10% from their lowest weight picked one of three treatments. Then they were followed for two full years.

Every single person finished. 100% follow-up in every group. That basically never happens.

The results, on one ruler

Four things jump out of that table, and each one matters.

1. The drug and the operation basically tied

13 kg versus 17 kg. 4.8 BMI points versus 5.5. The paper reports no significant difference between them.

One of those two options required general anesthesia.

2. The surgery group paid for those extra four kilograms

37% had serious complications. That's 6 people out of 16. Here's what that actually looked like, in their words, not ours:

• One patient developed an internal hernia and needed her abdomen opened to fix it
• One patient's ring eroded into her stomach and had to be removed endoscopically
• Three patients between them needed 37 separate scope procedures to stretch things open — one woman had it done 32 times, because she couldn't eat and kept vomiting

Thirty-two procedures. For a revision that was supposed to solve the problem.

We're not showing you that to scare you off surgery. Surgery is the right answer for some people and we'll tell you when. We're showing you because the brochure version of "revision surgery" doesn't include a woman getting scoped 32 times, and you deserve the full picture before you sign anything.

3. The "minimally invasive" endoscopic option barely did anything

This is the one being marketed hardest right now, so pay attention.

The surgeons narrowed the outlet from 22 mm down to 6 mm. That's a dramatic mechanical change. And it still only reversed 20% of the regained weight.

All 15 patients were unhappy. All 15 asked for medication instead. All 15 left the study at 12 months.

And here's the part that stings: both UnitedHealthcare and Aetna classify these endoscopic revision procedures as unproven, which means you'd likely be paying cash for it. We'll show you those documents in the next section.

4. The medication group's side effects were mild, and one thing was surprising

No serious complications. Nausea was common early on. But no reflux reported by anyone. No gallbladder problems. No pancreatitis — which the authors point out is different from what happens in people who take the same drug without having had surgery.

The finding that should calm you down most

Half the medication patients never reached the full dose. Nausea stopped them. The typical dose they settled at was about two-thirds of the maximum.

And the researchers found no relationship between the highest dose someone tolerated and how much weight they lost.

If you're scared of side effects, read that twice. On this evidence, you may not need the top dose. Sitting at a lower dose that you can actually live with may cost you nothing.

Where this study falls short

We're not going to oversell it.

Patients chose their own group. This wasn't randomized. People who pick surgery may be different from people who pick a needle.

It was one clinic in Switzerland. Small groups. And everyone had a gastric bypass — the authors say straight out that sleeve patients need their own study.

One more thing, and we'll show our work. The paper's own numbers disagree with each other. The abstract says 37% had serious complications. The discussion says 33%. Six out of sixteen is 37.5%, so 37% is the figure the paper's own math supports. We flag it because you should be able to check us, and because a page that hides a source's internal contradiction is a page you shouldn't trust.

And now the part that makes this argument stronger, not weaker

That study used liraglutide — the oldest and weakest of these drugs.

Since then:

• Semaglutide beat liraglutide roughly two to one on hitting 10% and 15% weight loss in post-surgery patients, in a group of 207 people
• Tirzepatide beat semaglutide 15.5% to 10.3% after a sleeve, in a group of 115
• And BARI-STEP — the randomized trial — got 18% with semaglutide

So the head-to-head against surgery was run with the least effective medicine available. Today's drugs would very likely do better.

We're labeling that as our conclusion, not a finding. Nobody has re-run that head-to-head with tirzepatide. Until someone does, it's a reasonable inference and not a fact.

The study authors' own recommendation, in their own paper: use the medication first. Save surgical revision for people who don't respond.

If you'd rather try the medicine before the operating room

That's what the doctors who ran that study recommended. And the drug that performed best in people like you is tirzepatide — sold as Zepbound®.

Ro carries Zepbound® and the Wegovy® pen. Starting is $39 for the first month, and Ro refunds that $39 if you turn out not to be eligible for a GLP-1. So finding out costs you nothing but a few minutes.

Check your GLP-1 eligibility on Ro →

Medication is billed separately. Full pricing is further down this page.

(Sticky mobile CTA activates here: "Check your eligibility →")

Will insurance even cover a revision? Read your insurer's own words.

Answer capsule: Often, no — and not because your paperwork was weak. UnitedHealthcare's commercial medical policy, effective May 1, 2026, covers revision bariatric surgery only for a technical failure or major complication, and states that revision "for any other indication than those listed above" is unproven and not medically necessary. Aetna has a weight-based door, but it opens only for people who never lost more than half their excess weight. Regaining weight with intact anatomy may fit neither.

This is the section that saves people six months of their life.

Both of these documents are free. Anyone can read them. As far as we can tell, nobody writing for patients has bothered.

The two policies, side by side

What that table actually means for you

Read the first row again.

If you had a sleeve, hit your goal weight, and then gained it back — and your anatomy is fine — UnitedHealthcare's policy has no door for you. Not a difficult door. No door. Regain that isn't caused by a mechanical failure is listed as unproven and not medically necessary.

And Aetna's weight-based door has a trap in it that almost nobody notices.

Door 1 opens for people who never lost half their excess weight. So if your surgery worked — if you hit your goal and then the weight came back — you may not fit Door 1. And if your pouch hasn't actually stretched, you don't fit Door 2 either.

The person the policy was built for is someone whose surgery never worked. Not someone whose surgery worked and then wore off.

Which leads to the sentence we wish someone had told a lot of people two years ago:

The revision you're being told to fight for may not be covered no matter how hard you fight. And the medication route isn't the consolation prize. For a lot of people it's the shorter road.

Two more things buried in these documents

If you're on a marketplace plan in one of 16 states, the UnitedHealthcare policy above doesn't govern you. The Individual Exchange version specifically doesn't apply in Alabama, Florida, Georgia, Indiana, Kansas, Louisiana, Mississippi, Nebraska, Ohio, Oklahoma, South Carolina, Tennessee, Texas, Virginia, Washington, or Wisconsin. If that's you, call and ask which policy document actually applies to your plan.

And check your own plan document before you read any medical policy. Both insurers say the same uncomfortable thing: a lot of employer plans exclude weight loss treatment entirely. If yours does, the medical policy doesn't matter, because the benefit was never there. That exclusion can also block coverage for the medication — so find out early, not after three appointments.

The flip side, honestly

If your anatomy really has changed, this whole section flips.

Stretched pouch. Dilated stoma. A leak. An obstruction. Severe reflux damage on a scope. Those are the exact things these policies do cover, and clearly. If that's your situation, revision surgery is likely the right answer and you're in a well-covered lane.

Go get the imaging. Get the scope. Don't let a web page talk you out of an operation you actually need.

If your revision door is closed but your drug coverage isn't

Here's what most people in your position don't realize: you have one of the strongest insurance cases in the entire GLP-1 market, and you don't know it.

Think about what your file already contains. A documented obesity diagnosis. Documented failure of every conventional treatment — that's what the surgery was. A documented surgical history. And conditions that came back when the weight did.

That is a strong prior authorization file. "Prior authorization" just means your insurer wants a doctor to justify the prescription before they pay for it.

Ro runs that paperwork for you and has a free coverage checker for Wegovy, Zepbound, and Ozempic.

Run Ro's free insurance check →

Free. No membership required to check. Takes a few minutes.

Which GLP-1 works best after bariatric surgery?

Answer capsule: Semaglutide has the strongest evidence in post-surgical patients because it's the only one tested in a randomized trial in this group — BARI-STEP, at 18.0% weight loss over 68 weeks. Tirzepatide has produced the largest results in real-world post-surgical data, averaging 15.5% total weight loss at six months after sleeve gastrectomy versus 10.3% for semaglutide in the same 115-patient study. Liraglutide is the oldest and weakest of the three.

Here's every result we could find in people who'd already had surgery, on the same ruler.

Why tirzepatide leads the real-world numbers — and the catch

In that 115-patient sleeve study, the gap looked huge:

But here's the correction that page-1 pages leave out. No semaglutide patient in that study ever went above 2 mg. The weight-management dose is 2.4 mg. So the semaglutide group was running below the full dose the whole time.

The gap is real. It's probably smaller than 15.5 versus 10.3 makes it look.

We're telling you that because a page that hands you the flattering version of a number and hides the caveat is a page that will eventually hand you something worse.

The honest number: about one in five don't respond

Look back at that "didn't lose 5%" column.

19.1% of post-surgery patients on semaglutide lost less than 5%. On liraglutide it was 27.1%.

This is not guaranteed. Roughly one in five people in your situation start this and don't get a meaningful result. If that's you, you'll know within a few months, and that information is itself useful — it's the thing that moves a revision conversation from "maybe" to "yes."

The reason people actually quit is money, not nausea

This surprised us.

Across those 19 studies, dropout ran anywhere from 11% to 63%. And in one of them, the number one reason people stopped wasn't side effects. It was cost.

Budget for twelve months before you start month one. We'll give you the real numbers further down.

After a bypass or sleeve, should you take the injection or the pill?

Answer capsule: Take the injection. Oral semaglutide is absorbed through the stomach lining using a helper ingredient called SNAC, which raises the pH right at the stomach wall so the drug survives. Bariatric surgery changes the stomach's surface area, acid level, and how long anything stays there — all three things that absorption depends on. A 2026 review in the journal Pharmaceutics concluded clinicians should prefer the injection after bariatric surgery until proper absorption data exists.

This is a mechanism problem, not a preference. And it's the finding we found that almost nobody has told you.

Why the pill is different

Semaglutide is a peptide — a fragile protein-type molecule. Stomach acid destroys it. So to make a pill version, the manufacturer bonded it to an absorption helper called SNAC (short for sodium N-[8-(2-hydroxybenzoyl)amino] caprylate — you'll never need that again).

SNAC works by raising the pH in a tiny zone right against the stomach lining, creating a protected pocket where the drug can survive long enough to cross into your blood.

That whole system needs three things: enough stomach surface, the right acid level, and enough time sitting still.

Here's how narrow the margin is even in a normal stomach. The pill's bioavailability — the share of the dose that actually reaches your bloodstream — is around 1%. And in healthy volunteers, drinking 8 ounces of water instead of 4 cut drug levels by about 40%.

That's a mechanism with no room to lose ground.

Now think about what your surgery did. A sleeve removed most of your stomach. A bypass left a pouch the size of an egg and rerouted food past the rest. Surface area, acid, and transit time — all three changed.

What fits after which surgery

The 2026 review in Pharmaceutics put it plainly: after major stomach surgery, clinicians should "preferably consider subcutaneous therapy until specific pharmacokinetic/clinical data are available." It also notes the product information itself says there is no therapeutic experience in bariatric patients.

And yes, this rules out the easy option

We know some of you came here hoping for a way around needles. We'd rather tell you the truth than sell you the comfortable thing.

The needle-free options — oral drops, sublinguals, GLP-1 gum — have no absorption data in people with your anatomy. Not "weak data." None. And when the whole selling point of a product is how it gets absorbed, and your absorption pathway is the exact thing that got rebuilt, that's not a gap you want to be the test case for.

If needles genuinely stop you, say that to a prescriber and solve it as a clinical problem. These are single-use, very fine, pen-style needles that most people describe as painless. Half the patients in that Swiss study injected themselves daily for two straight years with a 100% completion rate.

If you're already on the pill and it's working, that's real information. Don't stop on our say-so. Tell your prescriber about your surgery and get your weight and labs tracked properly.

Which GLP-1 provider will actually take you?

Answer capsule: Most national GLP-1 telehealth providers will consider patients with a bariatric surgery history — it is not an automatic disqualification. What separates them for someone with your history is three things: whether they carry tirzepatide, whether they'll let you sit at a lower dose without penalty, and whether anyone will handle your insurance paperwork.

Now the part you came for.

First, the answer that costs us money

Do not annualize the starter dose: The FDA label uses Zepbound 2.5 mg once weekly for four weeks of treatment initiation. It is not a maintenance dose. A real first-year estimate must follow the dose actually prescribed and add the care fee, not multiply one starter-month price by 12.

Your best first call is the bariatric program that did your surgery.

They have your operative report. They have your lowest weight on file. They have your old labs. And they can answer the one question that decides everything else — whether your pouch actually stretched.

Many bariatric programs now have an obesity medicine arm that prescribes these exact medications. If yours will prescribe, use them. Nothing below beats a team that already has your chart.

There's no link on that recommendation. Nobody pays us for it. We're putting it first anyway, because it's true, and because you already knew it and would have stopped trusting us if we'd skipped it.

If they won't, can't, or the wait is four months — keep reading.

What to look for

Four things, in this order:

1. An injection, not just a pill or an oral product
2. Tirzepatide access, since it's produced the biggest real-world numbers in this group
3. Willingness to go slow and stay low — half the patients in that head-to-head couldn't tolerate the top dose and lost the same amount anyway
4. Someone who handles insurance, because your file is stronger than you think

The comparison

Care cost is not total cost. Medication is a separate bill on most of these. Verify current pricing before you sign up — see the cost section below.

Ro — our pick for most people here

Ro is the best GLP-1 provider for bariatric revision for most readers, and the reasoning is specific to your situation rather than generic.

It carries the drug that performed best in people like you. Zepbound® is tirzepatide. Tirzepatide produced 15.5% at six months post-sleeve, with only a 2.9% non-response rate. Ro also carries the Wegovy® pen — the exact product and dose used in BARI-STEP.

It points its best feature at your best asset. Ro's insurance concierge handles prior authorization paperwork, and its free coverage checker covers Ozempic, Wegovy, and Zepbound pens. Most GLP-1 shoppers have a thin insurance case. Yours is unusually strong, and you likely don't know it.

And it removes the fear that brought you here. Your real question isn't "which company." It's "will anyone even take me?" Ro charges $39 for the first month and refunds that $39 if you're not eligible for a GLP-1. So finding out the answer costs you nothing.

Pricing, as of our last check: get started for $39, then as low as $74/month with an annual plan paid upfront. Standard monthly is $149. Medication is billed separately — Wegovy® pill from $149/mo, Wegovy® pen from $199/mo, Zepbound® from $299/mo. With insurance approved, you pay your plan's copay instead.

One real customer note on service speed, from a public Trustpilot review:

"Their service was quick. Everything was approved within 24 hours." — Carol Neel, invited Trustpilot review

One person's service experience. Approval times vary and depend on your insurance and clinical review. This is not a statement about weight loss results.

Now the honest part

Ro does not look inside your anatomy, and the membership does not include your medication.

If you need a scope, an X-ray, or a surgeon's read on whether your pouch stretched — your bariatric program is better and you should go there first. We said it above and we'll say it again here where it costs us the click.

And if you want one bundled bill with the medication included, Ro will annoy you. It's two charges, always. Here's a real customer being blunt about exactly that:

"The monthly membership does NOT include the medication." — Kimberly H., Trustpilot review

She's right. That's how it works.

But here's why that trade is worth making for you specifically. Because Ro isn't running a surgical clinic, it can put an FDA-approved brand-name injection and a full insurance department in front of you in days instead of the four-month wait at a bariatric program. And because it bills the drug separately instead of bundling it, when your insurance does approve — and with your file, there's a real chance it will — you pay a copay for the medication instead of a padded flat rate that quietly includes it.

That's the trade. No anatomy workup, no bundled bill. In exchange: the best drug for your situation, the paperwork done for you, and a decision in days.

You have a stronger case than you think. Find out for free.

A documented obesity diagnosis. Documented failure of every conventional treatment — your surgery is that documentation. A surgical history. Conditions that came back.

That's the file. Ro checks it against your plan for free, and if you don't qualify for a GLP-1 at all, your $39 comes back.

Check your eligibility and coverage on Ro →

Does this sound like your situation? Then this is a few minutes and no money to find out.

Sesame Care — if you want to pick your own clinician

When you're handing someone a surgical history, wanting to choose who reads it is a good instinct.

Sesame lets you browse clinicians and book a real video visit, and it carries the broadest brand-name list — Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda. Care starts around $59/month, with medication separate. It's also the better fit if you just need a prescriber and plan to fill through your own pharmacy benefit.

The catch: the platform doesn't make every listed clinician a post-bariatric expert. Provider choice only helps if you actually use it. Before you book, ask these five questions:

1. Do you regularly treat weight recurrence after a sleeve or bypass?
2. Will you review my operative report and weight history?
3. Which symptoms would send me back to bariatric surgery?
4. How will you monitor my labs and protein?
5. Can you coordinate with my surgical team?

Enhance MD — if you want labs run

Tirzepatide and semaglutide, repeat lab testing, same price at every dose, built for people who plateaued and want a stronger protocol.

That's a genuinely good match here for one reason: post-bariatric patients need periodic nutrient labs anyway — B12, iron, vitamin D — and you are by definition a plateau case. Note that these are compounded medications, which we explain below.

Form Health — if you want a dietitian in the room

We're including a provider that pays us nothing, because for one specific reader it's the right answer.

Form Health's model pairs an obesity-medicine physician with a registered dietitian, plus ongoing clinical support and FDA-approved medication when appropriate. Self-pay is publicly listed at $299/month, with labs and medication separate. Insurance may apply.

That's the most expensive care fee on this page. It's also the only one with nutrition built in — and given that BARI-STEP found muscle mass declining during treatment, in a population that may already be behind on protein, that's not a luxury feature. If you can afford it and you want the full team, it's a defensible choice.

One public service comment from their site:

"They are always pleasant, available and professional." — Clinton C., provider-hosted testimonial

One person's service experience. Not evidence of medical results.

Embody — the cash-pay lane if you have no coverage

If your plan excludes weight loss treatment entirely, insurance help is worth nothing to you and you need a straight cash price.

Embody is a low-cost cash-pay program with flat pricing, HSA/FSA eligibility, fast online onboarding, direct-to-door shipping, and 24/7 provider-guided support. It offers compounded semaglutide and tirzepatide, and it lets you change your dose or switch medications without extra cost.

That dose-flexibility point matters more for you than for almost anyone else. Half the patients in that Swiss study needed to sit below the top dose — and lost the same amount anyway. Being able to move down, or switch, without a billing fight is a real advantage in this exact situation.

Three things you must understand before you click.

First, compounded medications are not FDA-approved. A compounded drug is one a pharmacy mixes to order. The FDA does not review compounded drugs for safety, effectiveness, or quality before they're sold. That's a different regulatory category than Wegovy or Zepbound — not a knock-off of them, a different thing legally.

Second, and this follows directly: every study on this page was done with FDA-approved brand-name medication. BARI-STEP tested semaglutide 2.4 mg — the Wegovy product. Those results belong to that product. They cannot be transferred to a compounded product just because both get described with the word "semaglutide." We won't make that leap and you shouldn't let anyone make it for you.

Third: injections only. Embody offers a needle-free GLP-1 gum. For most people that's an interesting option. For you it isn't, for the absorption reasons above — there's no data on buccal or oral absorption in people whose stomach has been rebuilt. Take the injection.

Compounded medications are not FDA-approved. If you have insurance, price the covered route first.

Who should not use an online provider for this

We'd rather send you away than be wrong about you.

• Food gets stuck, repeat vomiting, ongoing pain, or you can't keep fluids down → your surgical team, today. Not a website.
• Diagnosed low blood sugar episodes after eating (post-bariatric hypoglycemia) → in-person care.
• Nutrient deficiencies that aren't under control → get those managed first.
• You're within a year of your original surgery → that period belongs to your surgical team.
• You're on Medicaid → Ro can't accept you. See our Medicaid GLP-1 coverage guide →
• You're genuinely unsure which of these you are → take the quiz →

Use this first-year cost formula instead of one made-up total

First-year medication path = care-program fees + the price of each dose month + required visits or labs not included − confirmed insurance or savings support.

First-year revision path = deductible + coinsurance + noncovered program requirements + travel or time off work + follow-up costs.

This is the comparison nobody can finish from a headline price. A cheap first month can become the more expensive year, while a high surgery quote can fall sharply when a covered benefit applies. Get both numbers in writing before you compare them.

What does each path actually cost?

Answer capsule: The cheapest published cash price we could find for a bariatric revision is $15,999 for a sleeve-to-bypass conversion. National estimates for revision run from roughly $16,000 to $35,000. Twelve months on a brand-name GLP-1 through Ro — annual-prepay membership plus Zepbound — runs about a dose-dependent first-year drug total—not $4,476 calculated from the initiation dose for all 12 months. That's roughly three and a half years of medication for the price of one operation.

Nobody puts both of these numbers on the same page. Here they are.

What a revision costs if you pay cash

Why those numbers disagree so much. It's not that one source is lying. It's procedure type, region, surgeon, facility, and — mostly — what the package actually includes. One surgeon writing about his own market put it bluntly: a $14,000 package with $4,000 of add-ons costs more than a $16,500 all-in one.

Get the exclusions list in writing. Not the price list. The exclusions list. That's where the surprise lives.

What twelve months of medication costs

The arithmetic, both directions

At annual-prepay membership ($74/mo) plus Zepbound at $299/mo, twelve months runs about a dose-dependent first-year drug total—not $4,476 calculated from the initiation dose for all 12 months.

The cheapest published cash revision is $15,999.

That's roughly three and a half years of medication for the price of one operation.

Now the other side, and it's a real argument. The medication isn't permanent. Stop it and the weight tends to return — that's true for these drugs generally, and it's true for you. The operation is one bill and then it's done. Over a long enough horizon, surgery can genuinely be the cheaper answer.

That's exactly why this is a real decision and not a slam dunk. What it is not is a decision you should make without seeing both numbers, which is the position almost everyone reading page 1 is in right now.

Two things to know about Ro's pricing before you sign up

Ro's own pages currently disagree on higher-dose Zepbound. One page shows up to $449/month; a separate official dose page shows $499. When two official pages conflict, what you see at checkout is what governs. Look at checkout.

Insurance coverage through Ro runs only through the Wegovy pen, the Zepbound autoinjector pen, and Ozempic. The pill options are cash-pay.

Both routes are usually HSA and FSA eligible. See our HSA/FSA guide for GLP-1s →

If the medication route fits your budget

The full number is membership plus medication. Ro shows you both before you commit, and the $39 start comes back if you don't qualify.

See Ro's current pricing and start your eligibility check →

No insurance? Compare Embody's flat cash pricing instead → Compounded medications are not FDA-approved.

What are the real safety issues with your anatomy?

Answer capsule: GLP-1 medications slow the stomach and commonly cause nausea, which needs extra attention in someone whose digestive tract has already been rebuilt. The FDA-approved labeling for Wegovy warns about severe gastrointestinal reactions, kidney injury from dehydration, and rare reports of food entering the lungs during procedures involving general anesthesia or deep sedation. It also states the medication is not recommended in people with severe gastroparesis.

We're not going to hand you a scary list with no context. We're going to give you the four things that actually change what you should do.

1. Nausea and vomiting are not just an inconvenience for you

Nausea was the most common side effect across the research — about 22% of 516 patients in the pooled analysis. In most people that's an annoyance that fades.

You're not most people. If your stomach is a sleeve or a small pouch, you have less room for error on food and fluid intake. Repeated vomiting isn't something to grit through. And the FDA labeling specifically warns about acute kidney injury from dehydration caused by severe GI reactions.

The practical rule: if you can't keep fluids down, that's a call to your provider, not a wait-and-see.

Some good news, though. One randomized trial found liraglutide may actually be better tolerated after bariatric surgery, with fewer stomach side effects than in people who haven't had surgery. And in the Swiss head-to-head, the medication group reported no reflux, no gallbladder problems, and no pancreatitis — which the authors point out differs from what happens in non-surgical patients on the same drug.

2. Muscle loss is the finding you should take seriously

BARI-STEP measured body composition, and lean soft tissue — muscle — went down during treatment.

This matters more for you than for the average person on a GLP-1, and here's why: you may already be behind on protein. Bariatric surgery limits how much you can eat. Add a medication that further reduces appetite, and protein intake is the first thing to slip.

Notice how the trial handled it. Both groups got a structured diet and resistance training specifically to preserve muscle. That wasn't decoration. It was part of the protocol.

Practical version: protein first at every meal, resistance training two or three times a week, and a provider who actually tracks it. This is the strongest argument on this page for picking a provider with real follow-up over one that ships you a pen and disappears.

3. Tell anyone doing a procedure on you that you're on this medication

This one is genuinely important and it's the one people don't know.

The Wegovy labeling describes rare reports of pulmonary aspiration — stomach contents getting into the lungs — during procedures with general anesthesia or deep sedation, because these medications slow how fast the stomach empties. Patients are told to inform their healthcare providers about any planned procedure.

Why does this matter to you more than to other people? Because you're a person who may well be getting a scope. Endoscopy, imaging, a revision consult — you're in the group most likely to end up sedated.

Do not stop your medication on your own. That decision belongs to the team doing the procedure and the person who prescribed it, working together. Just make sure both of them know.

4. Severe gastroparesis is a stop sign

The Wegovy labeling states it is not recommended in people with severe gastroparesis — a condition where the stomach empties much too slowly.

Don't diagnose yourself with that from symptoms. Slow emptying and post-surgical anatomy can feel similar and only testing tells them apart. But if you already have that diagnosis, say so early in the intake, not after month two.

And the standard warnings still apply

There are contraindications and boxed warnings on these medications that apply to everyone, surgery or not — including a personal or family history of certain thyroid cancers. Read the current prescribing information for whatever you're actually prescribed. We're not going to reproduce a partial homemade version of it here, because a partial safety list is worse than no list.

Related: GLP-1s and delayed stomach emptying → · GLP-1 hair loss: what's actually happening → · Protein targets on a GLP-1 →

How to walk into your appointment ready

Answer capsule: Bring four numbers and your surgery details, and the appointment goes differently. The four numbers are your weight before your first surgery, the lowest weight you reached after it, your weight today, and your height. Those four inputs produce the three figures that clinicians and insurers actually use to judge your case.

Here's the thing nobody tells you: three different rulers are being used to judge you, and they don't agree. You can qualify on one and fail another.

That third row is the one that surprises people. If your BMI is 32 right now and you've been assuming you're "not big enough anymore" to qualify for anything — you clear the label threshold for both medications. Most people who regained do.

Our free calculator does all three at once, from four inputs, and prints a one-page sheet you can hand to a clinician.

Run your numbers with the free calculator → — Four inputs. Nothing stored. Prints on one page.

What to bring

• Surgery type and date
• Name of the center that did it
• Your operative report, if you can get it
• Your lowest weight after surgery, and roughly when
• When the regain or the plateau started
• Any current stomach symptoms
• Recent labs — B12, iron and ferritin, vitamin D, folate, A1c, and a metabolic panel are what bariatric programs typically track
• Current medications and supplements
• Any past experience with a weight loss medication
• Insurance card

Five questions that actually change the plan

1. Does my insurer's policy have a door for weight regain, or only for mechanical failure? (Ask this first. It reorders everything else.)
2. Do you want imaging or a scope to check whether my pouch or stoma has stretched?
3. If we try medication first, what result at what week would change the plan? (This turns "let's see" into a decision point.)
4. Should I be on the injection rather than the pill, given my anatomy?
5. Do you prescribe these here, or do I need an outside prescriber?

How we built this page, and what we actually checked

Answer capsule: This page was built from primary documents — two insurers' published bariatric surgery medical policies, FDA-approved drug labeling, a 2026 randomized controlled trial, a 2021 prospective head-to-head study, and a 2025 meta-analysis of 19 studies. Where sources disagree with each other, we show both rather than picking the more convenient one.

What we verified

Where our sources contradict each other, and what we did

• The 2021 head-to-head paper disagrees with itself on the complication rate — 37% in the abstract, 33% in the discussion. Six of sixteen is 37.5%. We used 37% and showed you the math.
• Ro's own pages disagree on higher-dose Zepbound pricing, $449 versus $499. We told you checkout governs.
• Published revision costs span $16,000 to $35,000. We gave you the whole range instead of the flattering end.
• The BARI-STEP responder percentages we cross-checked against the trial's group size. All three resolve to whole numbers of patients. That's how we satisfied ourselves they were real before printing them.

What we could not verify

• Whether each individual telehealth intake form specifically screens for bariatric surgery history. Ask during intake. Don't assume.
• The exact recommendation order inside the full ASMBS 2026 statement text. We've characterized only what its published summary supports.
• One internal inconsistency in Aetna's bulletin about a specific procedure code. We've flagged it as an observation, not a claim about what Aetna will pay.

How we get paid, and what it doesn't change

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn a commission if you sign up with some of the companies on this page.

Here's what that doesn't buy. It doesn't change what the trials found. It didn't put your bariatric program — which pays us nothing — anywhere but first. It didn't get Form Health, which pays us nothing, into the comparison table. And it didn't stop us from telling you not to buy the needle-free option that would have been the easier sell.

Full advertising disclosure →

Frequently asked questions

Answer capsule: Below are the specific questions people ask after reading this far. Each answer stands on its own.

Can you take a GLP-1 after gastric sleeve or bypass?

Yes. A history of bariatric surgery is not a contraindication to a GLP-1 medication. The 2026 BARI-STEP randomized trial specifically enrolled adults at least one year past a sleeve or gastric bypass and found 18.0% average weight loss over 68 weeks with weekly semaglutide 2.4 mg. Individual suitability still depends on your symptoms, nutrition, other conditions, and whether your anatomy needs checking first.

Will insurance cover a GLP-1 after weight loss surgery?

It depends on your plan, not on your surgery. Coverage turns on whether your plan covers weight loss medication at all, the medication's approved use, your current eligibility, and prior authorization rules. A bariatric surgery history doesn't guarantee approval — but it does give you unusually strong documentation, since your surgery is itself proof that conventional treatment was tried and didn't hold.

What BMI do you need to qualify after bariatric surgery?

The FDA-approved labeling for Wegovy and Zepbound covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, sleep apnea, or high cholesterol. Most people who have regained weight after surgery clear that threshold. A BMI of 32 is well above the label minimum.

Is a GLP-1 safer than revision surgery?

In the one study that compared them in the same patients, the medication group had no serious complications over two years and the surgical revision group had a 37% serious complication rate — 6 of 16 people, including one internal hernia requiring open surgery and one patient needing 32 separate scope procedures. That was a single non-randomized study at one center, so it isn't the final word, but the risk difference was large and in one direction.

Can a GLP-1 fix a stretched pouch or an enlarged outlet?

Aetna’s current policy expressly includes a limited pathway involving a documented dilated gastric pouch or gastrojejunal stoma when the rest of its revision criteria are met. UnitedHealthcare’s published commercial policy does not state that same broad “stretched pouch or outlet” rule; it evaluates its named revision or conversion indications and the member’s plan terms. A plan exclusion can still end either claim before medical necessity is reviewed.

Can you take Rybelsus or the Wegovy pill after gastric bypass?

You can be prescribed it, but the injection is the better-supported choice. Oral semaglutide is absorbed through the stomach lining using an absorption helper that depends on stomach pH, surface area, and contact time — all three of which bariatric surgery changes. A 2026 review in Pharmaceutics recommended clinicians prefer injectable therapy after bariatric surgery until absorption data exists in these patients.

Is compounded semaglutide proven to work after bariatric surgery?

FDA status—verified August 17, 2026: Compounded semaglutide and tirzepatide are not FDA-approved. FDA lists the injection shortages as resolved, and the broad shortage-era enforcement-discretion periods ended in 2025. Patient-specific compounding may still occur when the applicable federal and state requirements are met; that is not a blanket pathway for mass-marketed copies. “Compounded,” “generic,” and “FDA-approved” do not mean the same thing.

No. Every study in this area used FDA-approved brand-name medication. Compounded drugs are mixed to order by a pharmacy and are not reviewed by the FDA for safety, effectiveness, or quality before being sold. Trial results from an FDA-approved product cannot be transferred to a compounded product on the basis of a shared ingredient name.

How long after bariatric surgery can you start a GLP-1?

There's no single universal cutoff, and any page that gives you one is guessing. The BARI-STEP trial required participants to be at least one year past surgery. An individual clinician may use different timing based on your recovery, symptoms, nutrition status, and the reason for treatment — which is why the first year after surgery belongs to your surgical team.

Does taking a GLP-1 mean my surgery failed?

No. Roughly one in five people who have bariatric surgery either don't lose enough weight or regain it, and the surgical societies now call this "weight recurrence" rather than failure, because obesity behaves as a chronic condition. Part of why surgery works is that it raises your body's own GLP-1 signaling; a GLP-1 medication restores that same signal when it fades.

What happens if I stop taking it?

Weight tends to return after stopping a GLP-1 medication. That's consistent across the broader research and it's the main long-term trade-off against a one-time operation. Ask about the long-term plan at your first appointment rather than after month three, and factor twelve months of cost into your decision — in one analysis of post-surgical patients, cost was the leading reason people quit, ahead of side effects.

Can a GLP-1 help me avoid revision surgery?

For some people, yes — but nobody can promise it. Medication cannot repair a structural problem, and no trial has directly randomized post-surgical patients to medication versus revision surgery. The authors of the one non-randomized head-to-head study recommended trying the medication first and reserving surgical revision for people who don't respond.

What if my original surgeon is no longer available?

Use the MBSAQIP accredited center finder, run jointly by the American College of Surgeons and ASMBS, with close to 1,000 participating sites in the US and Canada. Accredited centers routinely review operations performed elsewhere. You don't need the original surgeon to get your anatomy evaluated.

Can you take a GLP-1 after a lap band was removed?

Generally yes, and the evidence is arguably cleaner here than for sleeve or bypass. The pivotal STEP 1 trial excluded people with prior obesity surgery but made a specific exception for prior gastric banding when the device had been removed at least a year before screening. That suggests the researchers themselves viewed removed-band anatomy differently from sleeve or bypass anatomy.

Do all online GLP-1 providers accept people who've had bariatric surgery?

No, and you shouldn't assume. Ask specifically: do you accept patients after my surgery type, is there a minimum time since surgery, do you review the operative report, which symptoms would make you refer me back to surgery, and how do you monitor labs and protein. Ask before you pay, not after.

Where to go from here

Let's put it back together simply.

• Weight came back, anatomy is fine, you have insurance → Run Ro's free insurance check →
• Weight came back, no coverage, paying cash → See Embody's flat cash pricing → (compounded, not FDA-approved — injections, not the gum)
• You want a dietitian and a full clinical team → Form Health, $299/month self-pay
• You want to choose your own clinician → Browse Sesame clinicians →
• Food gets stuck, vomiting, pain, or sudden portion changes → your surgical team, and don't wait
• Less than a year out from surgery → your surgical team owns this period
• You're not sure which one you are → the quiz below

One last thing, and we mean it.

You already did the hardest thing anyone asks a person to do about their weight. You had surgery. The fact that your body pushed back doesn't undo that, and it doesn't mean you're out of options. It means you're at the next step of a long condition, with better tools than existed the year you had your operation.

The evidence in this article didn't exist five years ago. The randomized trial in people exactly like you was published this year.

You're not late. You're early.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

The anatomy-first decision matrix

Four questions. No account, no card. You get a personalized action plan — which type of provider fits your situation, what to bring to the appointment, and which questions to ask.

By the Weight Loss Provider Guide Research Team · Last verified: August 17, 2026 · Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn commissions from some providers listed. Advertising disclosure · Editorial policy · Corrections

This article is information, not medical advice. It is not a substitute for evaluation by a licensed clinician who knows your surgical history. Medication decisions, dose changes, and decisions about stopping treatment before a procedure should be made with your prescriber and your surgical team.